Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Lymphoma, Hodgkin. 22 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

[Complete title: AMC Protocol #085: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma]
Principal Investigator: Manoj Menon
Study Number: 2719.00
Phase: I/II

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

[Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)]
Principal Investigator: Ajay Gopal, MD
Study Number: 9111
Phase: I/II

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: I/II

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Rachel Salit
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (HEART)

[Complete title: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy]
Principal Investigator: Kasey Leger, MD
Study Number: ALTE11C2a
Phase: NA

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

[Complete title: A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies]
Principal Investigator: Todd Cooper
Study Number: TACL 2009-012
Phase: I

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

[Complete title: AHOD1221, A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1221

Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

[Complete title: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1331
Phase: III

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

[Complete title: Umbrella Long-term Follow-up Protocol]
Principal Investigator: Doug Hawkins, MD
Study Number: ALTE05N1

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

[Complete title: A Randomized, Open-Label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20121311
Phase: III

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

[Complete title: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies]
Principal Investigator: Bill Bensinger, MD
Study Number: 9219
Phase: I/II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials